Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of N-Methylhistamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 known ✓ | Q9Y5N1 | 2/20 | 0.96 |
| ▸ | HRH1 known ✓ | P35367 | 3/20 | 0.36 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.31 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.31 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.31 |
| ▸ | HTR1D known ✓ | P28221 | 1/20 | 0.31 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.31 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.31 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.31 |
| ▸ | HRH2 known ✓ | P25021 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.96 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.96 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.96 |
| ▸ | TSHR | P16473 | 1/20 | 0.96 |
| ▸ | MTOR | P42345 | 1/20 | 0.96 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
| ▸ | OGA | O60502 | 1/20 | 0.31 |
| ▸ | CPB2 | Q96IY4 | 5/20 | 0.31 |
| ▸ | CPB1 | P15086 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| N-Methylhistamine SCHEMBL2183879 | 1.00 | TDP1 (1.00) | TDP1HRH4HRH3CYP2C9CYP2C19 | |
| N-Methylhistamine SCHEMBL27340947 | 0.98 | — | — | |
| N-Methylhistamine SCHEMBL196356 | 0.98 | — | — | |
| N-Methylhistamine SCHEMBL19951025 | 0.96 | HRH4 (0.96) | TDP1HRH4HRH3CYP2C9CYP2C19 | |
| SCHEMBL14416066 | 0.86 | CYP2C9 (0.78) | TDP1HRH4HRH3CYP2C9CYP2C19 | |
| Hydrochloric Acid SCHEMBL17835480 | 0.83 | — | — | |
| N-Methylhistamine SCHEMBL25277752 | 0.82 | CYP2C9 (0.70) | TDP1HRH4HRH3CYP2C9CYP2C19 | |
| N-Methylhistamine SCHEMBL20359327 | 0.81 | HRH4 (0.68) | TDP1HRH4HRH3CYP2C9CYP2C19 | |
| SCHEMBL246132 | 0.80 | — | — | |
| SCHEMBL8288760 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240277668-A1 | HISTAMINE RECEPTOR AGONISTS FOR CANCER THERAPY IN CANCER PATIENTS UNRESPONSIVE TO CANCER IMMUNOTHERAPY AND WITH ELEVATED MYELOID DERIVED SUPPRESSOR CELLS | TSP THERAPEUTICS INC. | 2024-08-22 | — | — | US | claimed |
| EP-4376835-A1 | HISTAMINE RECEPTOR AGONISTS FOR CANCER THERAPY IN CANCER PATIENTS UNRESPONSIVE TO CANCER IMMUNOTHERAPY AND WITH ELEVATED MYELOID DERIVED SUPPRESSOR CELLS | TSP Therapeutics Inc. (US) | 2024-06-05 | — | — | EP | claimed |
| US-20240165082-A1 | ORALLY ADMINISTERED COMPOSITIONS FOR CANCER TREATMENT | TSP THERAPEUTICS INC. | 2024-05-23 | — | — | US | claimed |
| EP-4340838-A1 | ORALLY ADMINISTERED COMPOSITIONS FOR CANCER TREATMENT | Paz, Alberto (US) | 2024-03-27 | — | — | EP | claimed |
| WO-2023009261-A1 | HISTAMINE RECEPTOR AGONISTS FOR CANCER THERAPY IN CANCER PATIENTS UNRESPONSIVE TO CANCER IMMUNOTHERAPY AND WITH ELEVATED MYELOID DERIVED SUPPRESSOR CELLS | PAZ ALBERTO (US) | 2023-02-02 | — | — | WO | claimed |
| WO-2022245650-A1 | ORALLY ADMINISTERED COMPOSITIONS FOR CANCER TREATMENT | PAZ ALBERTO (US) | 2022-11-24 | — | — | WO | claimed |
| US-20250333424-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2025-10-30 | — | — | US | disclosed |
| US-20240277668-A1 | HISTAMINE RECEPTOR AGONISTS FOR CANCER THERAPY IN CANCER PATIENTS UNRESPONSIVE TO CANCER IMMUNOTHERAPY AND WITH ELEVATED MYELOID DERIVED SUPPRESSOR CELLS | TSP THERAPEUTICS INC. | 2024-08-22 | — | — | US | disclosed |
| EP-4376835-A1 | HISTAMINE RECEPTOR AGONISTS FOR CANCER THERAPY IN CANCER PATIENTS UNRESPONSIVE TO CANCER IMMUNOTHERAPY AND WITH ELEVATED MYELOID DERIVED SUPPRESSOR CELLS | TSP Therapeutics Inc. (US) | 2024-06-05 | — | — | EP | disclosed |
| US-20240165082-A1 | ORALLY ADMINISTERED COMPOSITIONS FOR CANCER TREATMENT | TSP THERAPEUTICS INC. | 2024-05-23 | — | — | US | disclosed |
| EP-4340838-A1 | ORALLY ADMINISTERED COMPOSITIONS FOR CANCER TREATMENT | Paz, Alberto (US) | 2024-03-27 | — | — | EP | disclosed |
| WO-2023009261-A1 | HISTAMINE RECEPTOR AGONISTS FOR CANCER THERAPY IN CANCER PATIENTS UNRESPONSIVE TO CANCER IMMUNOTHERAPY AND WITH ELEVATED MYELOID DERIVED SUPPRESSOR CELLS | PAZ ALBERTO (US) | 2023-02-02 | — | — | WO | disclosed |
| WO-2022245650-A1 | ORALLY ADMINISTERED COMPOSITIONS FOR CANCER TREATMENT | PAZ ALBERTO (US) | 2022-11-24 | — | — | WO | disclosed |
| US-5889178-A | N-(2,2-DIPHENYLETHYL)-DERIVATIVES | GLAXO GROUP LIMITED (GB) | 1999-03-30 | — | — | US | disclosed |
| WO-1998028319-A1 | 2-(PURIN-9-YL)-TETRAHYDROFURAN-3,4-DIOL DERIVATIVES | GLAXO GROUP LIMITED (GB) | 1998-07-02 | — | — | WO | disclosed |
| EP-0680488-B1 | 2,6-DIAMINOPURINE DERIVATIVES | GLAXO GROUP LTD (GB) | 1998-04-08 | — | — | EP | disclosed |
| CN-1112117-A | Imidazole-containing inhibitors of farnesyl protein transferase | BRISTOL MYERS SQUIBB CO (US) | 1995-11-22 | — | — | CN | disclosed |
| EP-0680488-A1 | 2,6-DIAMINOPURINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 1995-11-08 | — | — | EP | disclosed |
| EP-0675112-A1 | Imidazole-containing inhibitors of farnesyl protein transferase | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-10-04 | — | — | EP | disclosed |
| WO-1994017090-A1 | 2,6-DIAMINOPURINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 1994-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250333424-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, IRF3 | HRH3 4308/4885HRH1 3607/4885ADRA2B 4538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.